Back | Next |
home / stock / crtx / crtx message board
Subject | By | Source | When |
---|---|---|---|
Thx Tempe.. I still dont think these results are | McMagyar | investorshub | 10/28/2021 11:42:18 PM |
Analysis of the$ GAIN Trial PR data: | TempePhil | investorshub | 10/28/2021 10:53:26 PM |
Lotto $50 11/19 calls.. do or die | Motba | investorshub | 10/28/2021 4:49:11 PM |
In some 15 calls | lvhd | investorshub | 10/28/2021 4:27:20 PM |
Finally starting a recovery. Let's see if it | Porteño | investorshub | 10/28/2021 3:38:28 PM |
And the bleeding continues :( | bcapps66 | investorshub | 10/28/2021 1:37:14 PM |
-75% vs -76%... meh | Porteño | investorshub | 10/27/2021 8:47:06 PM |
Just when you think it wouldn't go lower....it | bcapps66 | investorshub | 10/27/2021 7:44:01 PM |
No bounce at all today...it just fell and splat! | bcapps66 | investorshub | 10/27/2021 6:31:31 PM |
Yes, extremely oversold. | Porteño | investorshub | 10/27/2021 3:50:22 PM |
Wow...down from $100 a month ago | bcapps66 | investorshub | 10/27/2021 3:47:27 PM |
I agree. I like the chart right now. | Porteño | investorshub | 10/27/2021 3:36:20 PM |
The drug appears to work for targeted group.. | McMagyar | investorshub | 10/27/2021 9:56:35 AM |
Penny Double $RUN!!! | Penny Double | investorshub | 10/27/2021 3:26:26 AM |
OUCH~! | TheFinalCD | investorshub | 10/27/2021 2:15:55 AM |
anyone holding through this? https://www.reuters.com/business/healthcare-pharmac | TheFinalCD | investorshub | 10/27/2021 2:14:56 AM |
I'll be looking at $7-$9 range for a | whosleftholdindabag | investorshub | 10/26/2021 9:56:10 PM |
Hello everybody, I'll be watching for the stock | whosleftholdindabag | investorshub | 10/26/2021 9:33:40 PM |
Merrill 6-25-21 report says: | ranchhand71 | investorshub | 07/03/2021 11:42:00 AM |
Here is some simple math for NEW INVESTORS!!!! | infitvest | investorshub | 05/02/2021 11:38:08 PM |
News, Short Squeeze, Breakout and More Instantly...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...